Revolution Medicines, Inc. (RVMD)
| Market Cap | 42.21B +388.8% |
| Revenue (ttm) | n/a |
| Net Income | -1.77B |
| EPS | -8.92 |
| Shares Out | 214.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,821,066 |
| Open | 198.53 |
| Previous Close | 195.92 |
| Day's Range | 194.80 - 202.02 |
| 52-Week Range | 42.18 - 224.31 |
| Beta | 1.41 |
| Analysts | Strong Buy |
| Price Target | 251.21 (+27.56%) |
| Earnings Date | Nov 4, 2026 |
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price target is $251.21, which is an increase of 27.56% from the latest price.
News
Revolution Medicines gets orphan designation for pancreatic cancer treatment
The FDA granted Revolution Medicines (RVMD)’ zoldonrasib orphan designation as a treatment of pancreatic cancer.
Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA
Revolution Medicines (RVMD) announced that the FDA has granted Breakthrough Therapy Designation to Rasonque, the company’s RAS multi-selective inhibitor, for treatment-naive metastatic pancreatic aden...
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering inno...
Revolution Medicines initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Revolution Medicines (RVMD) with an Overweight rating and $255 price target The firm says the companyis the leading RAS-targeted oncology franchise. Revolution is ...
Revolution Medicines price target raised to $230 from $215 at Stifel
Stifel analyst Laura Prendergast raised the firm’s price target on Revolution Medicines (RVMD) to $230 from $215 and keeps a Buy rating on the shares. The raised target accounts for…
New drug shows promise for lung cancer
Revolution Medicines CEO Dr. Mark Goldsmith discusses the clinical trial results from Rasonque on ‘FBN's Wall Street.'
Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.
2026 is the year of the cancer breakthrough, with innovations from Revolution Medicines and Moderna. "I'm almost tired of saying paradigm shift, but I haven't figured out a new phrase," one expert sai...
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering inno...
Revolution Medicines price target raised to $275 from $240 at Needham
Needham raised the firm’s price target on Revolution Medicines (RVMD) to $275 from $240 and keeps a Buy rating on the shares. The firm is updating its model to reflect…
Revolution Medicines price target raised to $265 from $220 at UBS
UBS raised the firm’s price target on Revolution Medicines (RVMD) to $265 from $220 and keeps a Buy rating on the shares.
Revolution Medicines price target raised to $275 from $240 at Guggenheim
Guggenheim raised the firm’s price target on Revolution Medicines (RVMD) to $275 from $240 and keeps a Buy rating on the shares. Following early FDA approval of daraxonrasib, now named…
Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent
Revolution Medicines attracted takeover interest but decided to go it alone. This week's FDA approval of its pancreatic cancer pill is the payoff.
Revolution Medicines price target raised to $246 from $227 at JPMorgan
JPMorgan raised the firm’s price target on Revolution Medicines (RVMD) to $246 from $227 and keeps an Overweight rating on the shares following the approval of Rasonque. Published first on…
Revolution Medicines price target raised to $251 from $203 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on Revolution Medicines (RVMD) to $251 from $203 and keeps an Outperform rating on the shares. Despite the muted move,…
Revolution Medicines price target raised to $248 from $230 at Raymond James
Raymond James analyst Sean McCutcheon raised the firm’s price target on Revolution Medicines (RVMD) to $248 from $230 and keeps a Strong Buy rating on the shares. Rasonque’s earlier-than-expected FDA…
Revolution Medicines price target raised to $260 from $230 at Oppenheimer
Oppenheimer raised the firm’s price target on Revolution Medicines (RVMD) to $260 from $230 and keeps an Outperform rating on the shares. The firm views the FDA approval of RASONQUE…
Revolution Medicines price target raised to $320 from $230 at Evercore ISI
Evercore ISI raised the firm’s price target on Revolution Medicines (RVMD) to $320 from $230 and keeps an Outperform rating on the shares. The firm updated its model following the…
Revolution Medicines price target raised to $280 from $195 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines (RVMD) to $280 from $195 and keeps a Buy rating on the shares following the FDA approval…
Revolution Medicines prices Rasonque at $39,800 for 30-day supply
Revolution Medicines (RVMD) disclosed that following FDA approval of Rasonque for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemi...
Revolution Medicines Transcript: FDA announcement
FDA approved RASONQUE (daraxonrasib) as the first targeted therapy for metastatic pancreatic cancer, based on phase III data showing a 60% reduction in risk of death and improved quality of life. The drug is available immediately in the U.S., with robust commercialization and patient support in place.
Revolution Medicines Slides: FDA announcement
Revolution Medicines has posted slides in relation to its latest quarterly earnings report, which was published on August 26, 2026.
Revolution Medicines Press release: FDA announcement
Revolution Medicines issued a press release on August 26, 2026, disclosing material business information to investors.
Revolution Medicines announces FDA approval of Rasonque in adults
Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration has approved RASONQUE once-daily oral tablets, for the treatment of adults with metastatic pancreatic adenocarcinoma wh...
U.S. FDA Approves Revolution Medicines' RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
This release contains multimedia assets available for download here
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.
Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,' has been granted approval in patients with pancreatic adenocarcinoma.